Online inquiry

IVTScrip™ mRNA-Human ACOT4, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK8835MR)

This product GTTS-WK8835MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ACOT4 protein. This product can be used in Oogenesis phase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_152331.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 122970
UniProt ID Q8N9L9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ACOT4, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK8835MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK6430MR IVTScrip™ mRNA-Human Carboxypeptidase M, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Carboxypeptidase M
GTTS-WK12914MR IVTScrip™ mRNA-Human AAK1, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AAK1
GTTS-WK3454MR IVTScrip™ mRNA-Human MMP9, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MMP9
GTTS-WK7265MR IVTScrip™ mRNA-Human ABHD15, (Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABHD15
GTTS-WK5915MR IVTScrip™ mRNA-Human PKC-alpha, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PKC-alpha
GTTS-WK18377MR IVTScrip™ mRNA-Human AKR1C3, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AKR1C3
GTTS-WK25875MR IVTScrip™ mRNA-Human ARG, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARG
GTTS-WK16848MR IVTScrip™ mRNA-Human AK3, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AK3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW